Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well gemcitabine works in treating patients with metastatic cancer of unknown primary.
Carcinoma of Unknown Primary
Drug: gemcitabine hydrochloride
Procedure: quality-of-life assessment
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit|
- Efficacy, in terms of improved quality of life and reduction of symptom distress [ Designated as safety issue: No ]
- Changes in symptom distress, pain, and quality of life at 8, 16, and 32 weeks [ Designated as safety issue: No ]
- Tumor response and duration [ Designated as safety issue: No ]
- Survival [ Designated as safety issue: No ]
|Study Start Date:||June 2006|
|Primary Completion Date:||February 2007 (Final data collection date for primary outcome measure)|
- Evaluate the efficacy of gemcitabine hydrochloride in patients with metastatic cancer of unknown primary (CUP), in terms of improved quality of life (QOL) (as measured by the FACT Physical Well Being subscale [FACT-G]) and reduction of symptom distress (as measured by the Memorial Symptom Assessment Scale Short Form Global Distress Index [MSAS-SF]).
- Define clinical benefit response using a QOL instrument in patients with CUP receiving gemcitabine hydrochloride.
- Correlate objective and/or evaluable tumor response with symptom and QOL response in these patients.
- Explore the association between symptom response, QOL response, and clinical benefit response in these patients.
- Evaluate changes in QOL in patients who have no symptom or objective response after treatment with gemcitabine hydrochloride.
- Correlate EuroQOL ratings with those using symptom instruments (MSAS-SF) and quality of life instruments (FACT-G).
- Evaluate changes in perceived QOL, as measured by the EuroQOL instrument, and how these changes relate to symptom response and QOL response.
- Evaluate the patient's assessment of treatment burden, as measured by a single question, and how this compares to symptom response and QOL response.
OUTLINE: This is an open-label, multicenter study.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43, followed by 1 week of rest (course 1). For all subsequent courses, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life (QOL) and symptom response are assessed at baseline and at weeks 8, 16, and 32 (end of treatment). Questionnaires include the Memorial Symptom Assessment Scale-Short Form, Functional Assessment of Cancer Therapy-General, Pain Visual Analog Scale, and EuroQOL. Patients' perception of symptom response and perception of treatment burden are also assessed.
After completion of study treatment, patients are followed periodically for up to 3 years.
PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00357630
Show 37 Study Locations
|Study Chair:||Victor T. Chang, MD||Veterans Affairs Medical Center - East Orange|
|Investigator:||Raymond S. Lord, MD||West Michigan Cancer Center|